Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections
AssigneePharmasset, Inc.
InventorsPeiyuan Wang, Lieven J. Stuyver, Kyoichi A. Watanabe, Abdalla Hassan, Byoung-Kwon Chun, Laurent Hollecker
Life of this patent
Estimating the term…
Abstract
The disclosed invention is a bicyclo[4.2.1]nonane and its pharmaceutically acceptable salt or prodrug, and its composition and method of use to treat Flaviviridae (Hepacivirus, Flavivirus, and Pestivirus) infections in a host, including animals, and especially humans.
Claims24
A method for the treatment of an HCV infection in a host comprising administering an effective amount of a compound of the formula (I):
- 75
- or a pharmaceutically acceptable salt thereof, wherein:
- (j) each R4 and R4 is independently hydrogen, halogen (F, Br, Cl, I), pseudohalogen, —CN, —NO2, lower alkyl of C1-C6, halogenated lower alkyl, hydroxyl, alkoxy, CH2OH, CH2OR6, —NH2, —NR6R7, or a residue of an amino acid;
- wherein at least one of R4 and R4′ is hydrogen;
- (k) each R5 and R5′ is independently hydrogen, halogen (F, Br, Cl, I), pseudohalogen, —CN, NO2, lower alkyl of C1-C6, or halogenated lower alkyl, hydroxyl, alkoxy, CH2OH, CH2OR6, —NH2, —NR6R7, or a residue of an amino acid;
- wherein at least one of R5 and R5′ is hydrogen;
- (l) each R6 and R7 is independently hydrogen, alkyl, halogenated alkyl, alkylene, alkenyl, carbocycle, aryl, heterocycle, heteroaryl, aralkyl or acyl;
- (m) R1 is hydrogen, lower alkyl, alkylene, alkenyl, carbocycle, aryl, heterocycle, heteroaryl, aralkyl, aminoalkyl, aminoaryl or aminoacyl of C1-C6;
- (n) R2 is oxygen, sulfur, —NR′ or —CR′2, wherein each R′ is independently hydrogen, lower alkyl, alkylene, alkenyl, aryl, or aralkyl of C1-C6;
- (O) R3 is hydrogen, lower alkyl, alkylene, alkenyl, carbocycle, aryl, heterocycle, heteroaryl, aralkyl, aminoalkyl, aminoaryl or aminoacyl of C1-C6 (C1, C2, C3, C4, C5, C6);
- (p) alternatively if R2 is —NR′, then R1 or R3 can come together with —NR′ to form a substituted or unsubstituted 5-7 membered ring that can include one or more heteroatoms;
- or
- (q) if R2 is —CR′2, then R′ or R3 can come together with —CR′2 to form a substituted or unsubstituted 5-7 membered ring that can include one or more heteroatoms;
- or
- (r) if R2 is —CR′2, R1 and R3 can come together with —CR′2 to form a substituted or unsubstituted bicyclic ring that can include one or more heteroatoms;
- optionally with a pharmaceutically acceptable carrier.
A method for the treatment of an HCV infection in a host comprising administering an effective amount of a compound of the general formula 1 (A-D), 2 (A-D), 3 (A-B), 4 (A-B), 5 (A-B), 6 (A-B), 7 (A-C) or 8 (A):
- 76 77 78
- or a pharmaceutically acceptable salt thereof, wherein:
- (a) each R4 and R4′ is independently hydrogen, halogen (F, Br, Cl, I), psuedohalogen, —CN, —NO2, lower alkyl of C1-C6, halogenated lower alkyl, 5 hydroxyl, alkoxy, CH2OH, CH2OR6, —NH2, —NR6R7, or a residue of an amino acid;
- wherein at least one of R4 and R4′ is hydrogen;
- (b) each R5 and R5′ is independently hydrogen, halogen (F, Br, Cl, I), psuedohalogen, —CN, NO2, lower alkyl of C1-C6, halogenated lower alkyl, hydroxyl, alkoxy, CH2OH, CH2OR6, —NH2, —NR6R7, or a residue of an amino acid;
- wherein at least one of R5 and R5′ is hydrogen;
- (c) each R6 and R7 is independently hydrogen, alkyl, halogenated alkyl, alkylene, alkenyl, carbocycle, aryl, heterocycle, heteroaryl, aralkyl or acyl;
- (d) R2 is oxygen, sulfur, —NR′ or —CR′2, wherein each R′ is independently hydrogen, lower alkyl, alkylene, alkenyl, aryl, or aralkyl of C1-C6;
- (e) each Z, Z′ and Z″ is independently CH, CX or N;
- (f) each X, X′ and X″ is independently hydrogen, halogen (F, Cl, Br or I), NH2, NHRc, NRcRc′, NHORc, NRcNRc′Rc″, OH, ORc, SH or SRc;
- (g) each Y and Y′ is O, S, NH, NRc, NORc or Se;
- (h) each Ra is hydrogen, lower alkyl, alkylene, alkenyl, carbocycle, aryl, heterocycle, heteroaryl, aralkyl, aminoalkyl, aminoaryl or aminoacyl of C1-C6;
- and
- (i) each Rc, Rc′ and Rc″ independently is hydrogen, lower alkyl, lower alkenyl, aryl, or arylalkyl such as unsubstituted or substituted phenyl or benzyl, cycloalkyl, cylcopropyl;
- optionally with a pharmaceutically acceptable carrier.
A method for the treatment of an HCV infection in a host comprising administering an effective amount of a compound of the general formula:
- 79
- or a pharmaceutically acceptable salt thereof, wherein:
- (a) each R4 and R4′ is independently hydrogen, halogen (F, Br, Cl, I), psuedohalogen, —CN, —NO2, lower alkyl of C1-C6, halogenated lower alkyl, hydroxyl, alkoxy, CH2OH, CH2OR6, —NH2, —NR6R7, or a residue of an amino acid;
- wherein at least one of R4 and R4′ is hydrogen;
- (b) each R5 and R5′ is independently hydrogen, halogen (F, Br, Cl, I), psuedohalogen, —CN, NO2, lower alkyl of C1-C6, halogenated lower alkyl, hydroxyl, alkoxy, CH2OH, CH2OR6, —NH2, —NR6R7, or a residue of an amino acid;
- wherein at least one of R5 and R5′ is hydrogen;
- (c) each R6 and R7 is independently hydrogen, alkyl, halogenated alkyl, alkylene, alkenyl, carbocycle, aryl, heterocycle, heteroaryl, aralkyl or acyl;
- (d) R2 is oxygen, sulfur, —NR′ or —CR′2, wherein each R′ is independently hydrogen, lower alkyl, alkylene, alkenyl, aryl, or aralkyl of C1-C6;
- (e) each Z, Z′ and Z″ is independently CH, CX or N;
- (f) each X, X′ and X″ is independently hydrogen, halogen (F, Cl, Br or I), NH2, NHRc, NRcRc′, NHORc, NRcNRc′ORc″, OH, ORc, SH or SRc;
- (g) each Y and Y′ is O, S, NH, NRc, NORc or Se;
- (h) each Ra is hydrogen, lower alkyl, alkylene, alkenyl, carbocycle, aryl, heterocycle, heteroaryl, aralkyl, aminoalkyl, aminoaryl or aminoacyl of C1-C6;
- (i) Rb is Rc, ORc, NH2,NHRc or NRCRC;
- and
- (j) each Rc, Rc′ and Rc″ independently is hydrogen, lower alkyl, lower alkenyl, aryl, or arylalkyl such as unsubstituted or substituted phenyl or benzyl, cycloalkyl, cylcopropyl;
- optionally with a pharmaceutically acceptable carrier.
A method for the treatment of an HCV infection in a host comprising administering an effective amount of a compound of the general formula:
- 80
- or a pharmaceutically acceptable salt thereof, optionally with a pharmaceutically acceptable carrier.
A method for the treatment of an HCV infection in a host comprising administering an effective amount of a compound of the general formula:
- 81 82 83 84 85
- or a pharmaceutically acceptable salt thereof, optionally with a pharmaceutically acceptable carrier.
A compound of the formula (I):
- 86
- or a pharmaceutically acceptable salt thereof, wherein:
- (a) each R4 and R4′ is independently hydrogen, halogen (F, Br, Cl, I), pseudohalogen, —CN, —NO2, lower alkyl of C1-C6, halogenated lower alkyl, hydroxyl, alkoxy, CH2OH, CH2OR6, —NH2, —NR6R7, or a residue of an amino acid;
- wherein at least one of R4 and R4′ is hydrogen;
- (b) each R5 and R5′ is independently hydrogen, halogen (F, Br, Cl, I), pseudohalogen, —CN, NO2, lower alkyl of C1-C6, halogenated lower alkyl, hydroxyl, alkoxy, CH2OH, CH2OR6, —NH2, —NR6R7, or a residue of an amino acid;
- wherein at least one of R5 and R5′ is hydrogen;
- (c) each R6 and R7 is independently hydrogen, alkyl, halogenated alkyl, alkylene, alkenyl, carbocycle, aryl, heterocycle, heteroaryl, aralkyl or acyl;
- (d) R1 is hydrogen, lower alkyl, alkylene, alkenyl, carbocycle, aryl, heterocycle, heteroaryl, aralkyl, aminoalkyl, aminoaryl or aminoacyl of C1-C6;
- (e) R2 is oxygen, sulfur, —NR′ or —CR′2, wherein each R′ is independently hydrogen, lower alkyl, alkylene, alkenyl, aryl, or aralkyl of C1-C6;
- (f) R3 is hydrogen, lower alkyl, alkylene, alkenyl, carbocycle, aryl, heterocycle, heteroaryl, aralkyl, aminoalkyl, aminoaryl or aminoacyl of C1-C6;
- (g) alternatively if R2 is —NR′, then R1 or R3 can come together with —NR′ to form a substituted or unsubstituted 5-7 membered ring that can include one or more heteroatoms;
- or
- (h) if R2 is —CR′2, then R1 or R3 can come together with —CR′2 to form a substituted or unsubstituted 5-7 membered ring that can include one or more heteroatoms;
- or
- (i) if R2 is —CR′2, R1 and R3 can come together with —CR′2 to form a substituted or unsubstituted bicyclic ring that can include one or more heteroatoms.
A compound of the general formula 1 (A-D), 2 (A-D), 3 (A-B), 4 (A-B), 5 (A-B), 6 (A-B), 7 (A-C) or 8 (A):
- 87 88 89
- or a pharmaceutically acceptable salt thereof, wherein:
- (a) each R4 and R4′ is independently hydrogen, halogen (F, Br, Cl, I), psuedohalogen, —CN, —NO2, lower alkyl of C1-C6, halogenated lower alkyl, hydroxyl, alkoxy, CH2OH, CH2OR6, —NH2, —NR6R7, or a residue of an amino acid;
- wherein at least one of R4 and R4′ is hydrogen;
- (b) each R5 and R5′ is independently hydrogen, halogen (F, Br, Cl, I), psuedohalogen, —CN, NO2, lower alkyl of C1-C6, halogenated lower alkyl, hydroxyl, alkoxy, CH2OH, CH2OR6, —NH2, —NR6R7, or a residue of an amino acid;
- wherein at least one of R5 and R5′ is hydrogen;
- (c) each R6 and R7 is independently hydrogen, alkyl, halogenated alkyl, alkylene, alkenyl, carbocycle, aryl, heterocycle, heteroaryl, aralkyl or acyl;
- (d) R2 is oxygen, sulfur, —NR′ or —CR′2, wherein each R′ is independently hydrogen, lower alkyl, alkylene, alkenyl, aryl, or aralkyl of C1-C6;
- (e) each Z, Z′ and Z″ is independently CH, CX or N;
- (f) each X, X′ and X″ is independently hydrogen, halogen (F, Cl, Br or I), NH2, NHRc, NRcRc′, NHORc, NRcNRc′Rc″, OH, ORc, SH or SRc;
- (g) each Y and Y′ is O, S, NH, NRc, NORc or Se;
- (h) each R1 is hydrogen, lower alkyl, alkylene, alkenyl, carbocycle, aryl, heterocycle, heteroaryl, aralkyl, aminoalkyl, aminoaryl or aminoacyl of C1-C6;
- and
- (i) each Rc, Rc′ and Rc″ independently is hydrogen, lower alkyl, lower alkenyl, aryl, or arylalkyl such as unsubstituted or substituted phenyl or benzyl, cycloalkyl, cylcopropyl.
A compound of the general formula:
- 90
- or a pharmaceutically acceptable salt thereof, wherein:
- (a) each R4 and R4′ is independently hydrogen, halogen (F, Br, Cl, I), psuedohalogen, —CN, —NO2, lower alkyl of C1-C6, halogenated lower alkyl, hydroxyl, alkoxy, CH2OH, CH2OR6, —NH2, —NR6R7, or a residue of an amino acid;
- wherein at least one of R4 and R4′ is hydrogen;
- (b) each R5 and R5′ is independently hydrogen, halogen (F, Br, Cl, I), psuedohalogen, —CN, NO2, lower alkyl of C1-C6, halogenated lower alkyl, hydroxyl, alkoxy, CH2OH, CH2OR6, —NH2, —NR6R7, or a residue of an amino acid;
- wherein at least one of R5 and R5 is hydrogen;
- (c) each R6 and R7 is independently hydrogen, alkyl, halogenated alkyl, alkylene, alkenyl, carbocycle, aryl, heterocycle, heteroaryl, aralkyl or acyl;
- (d) R1 is oxygen, sulfur, —NR′ or —CR′2, wherein each R′ is independently hydrogen, lower alkyl, alkylene, alkenyl, aryl, or aralkyl of C1-C6;
- (e) each Z, Z′ and Z″ is independently CH, CX or N;
- (f) each X, X′ and X″ is independently hydrogen, halogen (F, Cl, Br or I), NH2, NHRc, NRcRc′, NHORc, NRcNRc′Rc″, OH, ORc, SH or SRc;
- (g) each Y and Y′ is O, S, NH, NRc, NORc or Se;
- (h) each Ra is hydrogen, lower alkyl, alkylene, alkenyl, carbocycle, aryl, heterocycle, heteroaryl, aralkyl, aminoalkyl, aminoaryl or aminoacyl of C1-C6;
- (i) Rb is Rc, ORc, NH2, NHRc or NRCRC;
- and
- (j) each Rc, Rc′ and Rc″ independently is hydrogen, lower alkyl, lower alkenyl, aryl, or arylalkyl such as unsubstituted or substituted phenyl or benzyl, cycloalkyl, cylcopropyl.
A compound of the general formula:
- 91
- or a pharmaceutically acceptable salt thereof.
A compound of the general formula:
- 92 93 94 95 96
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.